Diamyd Medical AB
Company Profile
Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWET: +46 86610026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
42
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,171.90 | 51.30 | -0.56% |
| CAC 40 | 8,274.57 | 53.29 | -0.64% |
| DAX 40 | 24,066.70 | 22.48 | 0.09% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,559.58 | 49.48 | -0.47% |
| HKSE | 26,138.82 | 191.50 | 0.74% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 59,441.94 | 1,307.70 | 2.25% |
| NZX 50 Index | 13,094.35 | 17.77 | 0.14% |
| S&P 500 | 7,022.95 | 55.57 | 0.80% |
| S&P/ASX 200 | 8,956.60 | 60.60 | -0.67% |
| SSE Composite Index | 4,043.98 | 16.78 | 0.42% |